Nathan J. Dowden
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Nathan J. Dowden
Nathan J. Dowden is recorded as Board Member at Entrada Therapeutics, Inc. (TRDA). Entrada Therapeutics, Inc. reported in an 8-K filed January 3, 2024 that Nathan J. Dowden was appointed President, effective January 1, 2024. The proxy statement of Entrada Therapeutics, Inc. reports total compensation of $2,223,497 for Nathan J. Dowden in fiscal 2025, including a base salary of $499,200. Disclosed compensation is on record for 6 fiscal years.
“On December 29, 2023, the Board of Directors (the "Board") of Entrada Therapeutics, Inc. (the "Company") appointed Nathan J. Dowden, the Company's Chief Operating Officer, to serve as the Company's President, effective as of January 1, 2024 (the "Effective Date"), in addition to his role as the Company's Chief Operating Officer, replacing Dipal Doshi, the Company's Chief Executive Officer.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2024-01-01–present
-
Current
2019-01-01–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Entrada Therapeutics, Inc.
Other people whose current roles at this company are on record from its filings.
- Bernhardt Zeiher Board Member
- Bernhardt Zeiher, M.D. Board Member
- Kory Wentworth Board Member
- Kush M. Parmar, M.D., Ph.D. Board Member
- Maha Radhakrishnan Board Member
- Natarajan Sethuraman Board Member
- Peter S. Kim Board Member
- Peter S. Kim, Ph.D. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Entrada Therapeutics, Inc. (TRDA) | President and Chief Operating Officer | $499,200 | $2,223,497 |
| 2024 | Entrada Therapeutics, Inc. (TRDA) | President and Chief Operating Officer | $480,000 | $2,460,688 |
| 2023 | Entrada Therapeutics, Inc. (TRDA) | President and Chief Operating Officer | $456,501 | $1,485,455 |
| 2022 | Entrada Therapeutics, Inc. (TRDA) | President and Chief Operating Officer | $440,000 | $1,540,389 |
| 2021 | Entrada Therapeutics, Inc. (TRDA) | Chief Operating Officer | $378,532 | $2,312,017 |
| 2020 | Entrada Therapeutics, Inc. (TRDA) | Chief Operating Officer | $354,488 | $561,497 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.